In our endocrine resistant breast cancer cell models, MYC inhibition increased both JNK activation and LC3II levels, with an associated increased in hibition of cell growth in glutamine only conditions. Further studies are needed to in vestigate how MYC controls stress signaling mediated through JNK and cell death pathways. Autophagosome for mation and the accumulation of p62 SQSTM1 can trigger cell death through apoptosis during cellular stress, likely reflecting the inability to use autophago some content degradation to feed intermediate metabol ism. Thus, cellular metabolic status are clearly important in triggering specific MYC mediated functions. Within a tumor, cancer cells can e perience glucose deprivation due to an inadequate vasculature or drug treatment.
Short term inhibition of glycolysis may initiate UPR mediated responses that subsequently induce apoptosis in most cells but can also promote survival in a small fraction of cells until an adequate energy supply becomes available to enable both cell survival and proliferation. Indeed, in bortezomib induced cell death, MYC has been shown to bind to pro apoptotic BCL2 proteins, NO A and BIM, and cooperate with EGR1. Thus, MYC induced cell death in cancer cells warrants further elucidation. Increased activation of MYC in antiestrogen resistant cells is also associated with their increased dependence on glutamine and glucose for cell survival. However, the presence of glutamine in glucose deprived conditions initiated an UPR mediated pathway that killed most cells via apoptosis but allowed the survival of a small minor ity.
In LCC9Gln cells, which survived in media contain ing glutamine but no glucose, MYC levels were reduced and GLS GAC levels were increased when compared with the parental antiestrogen resistant LCC9 cells. These adaptations may ensure the appropriate balance be tween the levels of glutamine versus glutamate needed for the cells to survive in glucose deprived conditions. Glu tamine alone can sustain survival of a small cell population in the absence of glucose, albeit with a significantly de creased rate of cell proliferation. Molecular characterization of the multiple passages of LCC9Gln ver sus parental cells is underway and will help elucidate the MYC mediated and UPR regulated adaptive pathway.
E cessive systemic energy demand in cancer can lead to cache Carfilzomib ia, which affects a large number of cancer pa tients and results in the progressive loss of muscle and adipose tissue mass. To date, it is unclear how therapeutic interventions can safely alter the energy de mand of cancer cells within tumors without necessarily inducing additional metabolic problems for the host. While a tumor to liver Cori cycle is implicated in meet ing glucose demands, a tumor to muscle cycle is impli cated in meeting the glutamine demands of growing tumors.
Related posts:
- Breast cancer preferentially spreads to bone Tumor cells can dev
- In breast cancer, changes to FGF signaling are con sidered essent
- Iyengar Yoga May Improve Fatigue in Breast Cancer Survivors
- Elesclom RFS in cohorts of patients with ER breast cancer treated with
- SMAD6 reduction inhibits cancer cell development and induces ap